GammaDelta

GammaDelta was founded by Abingworth to explore the potential of gamma delta (γδ) T cells to create improved immunotherapy of cancer and other serious diseases. Early in its history, the company formed a strategic collaboration with Takeda under which the pharma company, together with Abingworth, committed up to $100 million in funding in return for an exclusive option to acquire GammaDelta. In 2021 it exercised that option, thereby acquiring GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, both blood-derived and tissue-derived, in addition to early-stage cell therapy programs.